🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Diabetic Macular Edema
Clinical trial register · United States · industry-sponsored

Diabetic Macular Edema Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9109 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Sep 2026, 04:27 UTC
9109
Studies in scope
industry-sponsored, all four open statuses
4946
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 13 Florida 12 Illinois 8 Arizona 8 Maryland 7
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Genentech, Inc.3 EyePoint Pharmaceuticals, Inc.2 Hoffmann-La Roche2 AiViva BioPharma, Inc.1 Eclipse Life Sciences, Inc.1
State
California13 Florida12 Illinois8 Arizona8 Maryland7
All 33 states
Target enrolment
to
16 of 9109 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
NCT07553429Diabetic Macular Edema
Boehringer Ingelheim
Phase 1/2
49
Arizona, California, Connecticut, Florida, New York, North Carolina, North Dakota, Ohio
2026-05-14
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
NCT07425522Diabetic Macular Edema
Genentech, Inc.
Phase 1
93
Arizona, California, Florida, Maryland, Pennsylvania, Tennessee, Texas, Virginia
2026-04-21
Active, closed
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
EyePoint Pharmaceuticals, Inc.
Phase 3
240
California, Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Louisiana
2026-02-16
Active, closed
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449923Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
EyePoint Pharmaceuticals, Inc.
Phase 3
240
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2026-02-09
Active, closed
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
NCT06536491Diabetic Macular Edema
Eclipse Life Sciences, Inc.
Phase 1/2
75
Florida
2024-08-19
Active, closed
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
NCT06491914Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Regeneron Pharmaceuticals
Phase 3
1,126
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Maryland
2024-07-24
Recruiting
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
NCT05802329Center Involved Diabetic Macular Edema, Diabetic Macular Edema
Ocugen
Phase 1
24
Florida, Pennsylvania, Texas, Wisconsin
2024-01-13
Active, closed
4D-150 in Patients With Diabetic Macular Edema
NCT05930561Diabetic Macular Edema, Diabetic Retinopathy
4D Molecular Therapeutics
Phase 2
72
Maryland, Oregon, Pennsylvania, Texas, Virginia
2023-08-09
Active, closed
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
NCT05698329Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema
AiViva BioPharma, Inc.
Phase 1
19
California, Oregon, Texas
2023-03-02
Active, closed
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
NCT06847854Diabetic Macular Edema
Genentech, Inc.
Phase 1
151
Arizona, Arkansas, California, Florida, Maryland, Michigan, Minnesota, Mississippi
2022-12-08
Active, closed
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
Hoffmann-La Roche
Observational
6,000
Arizona, California, Florida, Illinois, Kentucky, Maryland, Michigan, Pennsylvania
2022-11-21
Active, closed
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
NCT05387837Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Ashvattha Therapeutics, Inc.
Phase 2
50
California, Illinois, Indiana, Maryland, Massachusetts, Missouri, New Jersey, Pennsylvania
2022-08-31
Active, closed
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
NCT05607810Diabetic Macular Edema, Diabetic Retinopathy
Adverum Biotechnologies, Inc.
Observational
22
California, Nevada, Pennsylvania, Texas
2022-08-10
Active, closed
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
NCT05224102Diabetic Macular Edema
Genentech, Inc.
Phase 4
218
Arizona, California, Colorado, District of Columbia, Florida, Illinois, Maryland, Michigan
2022-02-28
Active, closed
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
NCT04469595Diabetic Macular Edema
Alimera Sciences
Phase 4
300
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Louisiana
2020-08-31
Active, closed
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
NCT04108156Diabetic Macular Edema
Hoffmann-La Roche
Phase 3
672
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2019-09-30
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/diabetic-macular-edema

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.